Hemp Archives - InvestorWire (IW)

Wednesday Nov 15, 2023 - 3:26 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Advance Patented DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for a growing range of applications including oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and more. Through previous clinical trials, DehydraTECH-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks. “That we were able to lower blood pressure in our…

Friday Nov 03, 2023 - 2:53 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Proven Superior in Research

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track to submit an Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial HYPER H23-1. “Lexaria’s IND submission builds on five previous human clinical studies conducted from 2018 to 2022 and is integral to the successful filing and review of the submission. These studies were carried out in…

Friday Oct 20, 2023 - 3:29 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Committed to R&D, Eyeing Excellent Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator seeking to enhance the bioavailability of multiple active pharmaceutical ingredients using its patented DehydraTECH(TM) drug delivery technology platform. The company continues to devote an increasing proportion of its resources and focus toward research and development (“R&D”) as part of its overall goal to establish areas of investigation for commercial pursuits and reduce risks of the unknown…

Monday Oct 02, 2023 - 2:39 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Nicotine Pouch Demonstrates Advantages over Competition

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported results from its human oral nicotine study NIC-H22-1, comparing Lexaria’s DehydraTECH(TM)-nicotine tobacco-free pouch to world-leading brands ZYN(R) and on! “Using measurements to determine the median time required to reach comparable nicotine concentrations within the bloodstream (‘Tmax’), Lexaria exhibited higher levels of certain pleasurable effects over the competition. DehydraTECH also provided the…

Friday Sep 15, 2023 - 2:50 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) New Subsidiary Maximizing Patented DehydraTECH(TM) in Various Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the incorporation of a new wholly owned subsidiary under the name Lexaria Nutraceutical Corp. (“LEXX Nutra”). “LEXX Nutra will keep with Lexaria’s overall strategy of maximizing the company’s patented DehydraTECH(TM) technology in various markets. Lexaria has issued an exclusive, perpetual license to LEXX Nutra, allowing the use of DehydraTECH to create…

Friday Sep 08, 2023 - 12:23 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) ‘Strategically Important’ Patent Grants Protection in One of World’s Leading Oral Nicotine Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently celebrated the receipt of U.S. patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine.” The patent covers various forms and sources of nicotine, including nicotine benzoate, nicotine polacrilex, nicotine citrate, nicotine detartrate, and many others, for use in sublingual delivery formats like oral pouches. “The new U.S. patent is remarkable…

Wednesday Aug 23, 2023 - 1:45 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Launching IND Program on DehydraTECH-CBD for Hypertension

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been published in eight peer-reviewed articles across six different publications. “The most recent publication in June 2023 in the peer-reviewed International Journal of Molecular Sciences is ‘Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study.’…

Friday Jul 14, 2023 - 2:22 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Study Reveals ‘Most Convincing Evidence’ of CBD’s Anti-Inflammatory Actions in Humans

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced additional findings from its human clinical study HYPER-H21-4, completed last year. “The hypertension study sought to evaluate DehydraTECH-processed cannabidiol (“CBD”) as a potential antihypertensive medication and already achieved primary efficacy and safety objectives. According to the company, the study also demonstrated significant reductions in several pro-inflammatory biomarkers – interleukin (‘IL’) 8, 10 and 18 – known to be…

Monday Jul 03, 2023 - 12:09 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen Hormone than Control

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently completed its animal study HOR-A22-1, which showed that the company’s patented DehydraTECH(TM) technology platform significantly enhanced the oral delivery of the estrogen hormone estradiol. “The study found that the DehydraTECH-estradiol composition resulted in a maximum concentration in the bloodstream (‘Cmax’) of 5.65 ng/mL, which was approximately 900% higher than the control formulation’s…

Monday Jun 12, 2023 - 12:55 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Experienced Financial Professional as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of a new chief financial officer. Effective immediately, Mike Shankman will serve as outsourced CFO. An experienced accounting and finance professional, Shankman has held senior positions with companies in the biotechnology, medical devices and software-as-a-service industries. As a consultant with NOW CFO, one of his current clients is a…

Friday Jun 09, 2023 - 10:39 am

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio of Worldwide Patents

Lexaria Bioscience Corp. (NASDAQ: LEXX), the global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs through its patented DehydraTECH(TM) technology, recently announced it had received notification of four newly awarded or allowed patents. “The new patents will add to Lexaria’s growing portfolio and, upon award, will bring the total number of patents granted worldwide to 32, with several…

Monday Apr 17, 2023 - 1:22 pm

InvestorNewsBreaks – Prime Harvest Inc. Eyes Continued Growth and Expansion with Recently Launched Reg A+ Offering

Prime Harvest, a tech-focused legal cannabis enterprise and parent company to SoCal’s premier dispensary JAXX Cannabis, recently launched Weed 4 The People – the company’s Reg A+ offering that allows the public to own a piece of the company for as little as $4.20 per share at a minimum of 100 shares. “Prime Harvest aims to raise upwards of $42M to fund the expansion of…

Friday Apr 14, 2023 - 12:52 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Positive Results in First Diabetes Study

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability of and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery with its patented DehydraTECH(TM). “Most recently, a company announcement indicates that a just-completed DIAB-A22-1 diabetes study has produced at least three positive outcomes, including weight loss in obese diabetic-conditioned animals…

Monday Apr 03, 2023 - 3:18 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Foundation for Improving Effectiveness of Lipophilic Drugs, APIs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is positioned for opportunity with its patented DehydraTECH(TM) technology and its wide-reaching potential. “Lexaria’s DehydraTECH is designed to formulate and deliver lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (‘APIs’). DehydraTECH increases the effectiveness of and improves the way APIs enter the bloodstream. The benefits of consuming a DehydraTECH-enabled drug or product include: speed…

Friday Mar 24, 2023 - 12:34 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Efforts to Boost Commercial Prospects ‘Paying off in Spades’

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology. Lexaria is continuing and/or initiating discussions with several larger companies in Europe and North America regarding the licensed use of its technology for both consumer and pharmaceutical sectors. “The materialization of such partnerships hinges on a number of must-haves. Firstly, there must be a tangible product that…

Friday Mar 17, 2023 - 1:29 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moving Closer to Providing Alternative Hypertension Treatment with DehydraTECH(TM)-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported additional findings from its most comprehensive clinical study yet, HYPER-H21-4. “The findings showed that DehydraTECH-CBD resulted in a statistically significant reduction in average baseline serum catestatin concentrations of 13.50 ng/mL to just 9.65 ng/mL after five weeks of dosing, representing a 28.5% drop. In addition, mean arterial pressure significantly dropped by…

Monday Mar 13, 2023 - 2:47 pm

InvestorNewsBreaks – Prime Harvest Inc. Secures Reg A+ Qualification, Eyes New Heights of Opportunity

Prime Harvest, a technology focused, full-service cannabis company, recently announced that its Regulation A+ offering, which seeks to raise up to $42 million, had been qualified by the U.S. Securities and Exchange Commission (“SEC”). “The company has announced that gross proceeds from the equity raising will be destined towards the acquisition of licensed assets, the development of Prime Harvest’s direct-to-consumer application, expansion of the company’s…

Wednesday Mar 08, 2023 - 3:14 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Improves Product Performance Across Multiple Categories

Lexaria (NASDAQ: LEXX) is a global innovator in drug delivery platforms. “The company’s patented DehydraTECH(TM) technology enhances the performance of multiple categories of fat-soluble active molecules and drugs available in various formats, including oral ingestible, oral buccal/sublingual and topical products. According to Lexaria, its technology ‘is best thought of as an additional layer that improves the effectiveness of existing or planned new products for companies…

Friday Feb 24, 2023 - 3:06 pm

InvestorNewsBreaks – Prime Harvest Inc. Delivering Excellence in Legal Access to Cannabis, Best-in-Class Experiences

Prime Harvest is a full-service cannabis company that focuses on licensing, acquisition, compliance management, and direct-to-consumer operations. The company aims to provide first-in-class cannabis experiences while enriching local stakeholders. “Social initiatives and philanthropy have always been a part of Prime Harvest Inc.’s mission. The company is a proud member of the Community Alliance Program (‘CAP’), which provides assistance for educational programs, veterans, urban farms, and…

Friday Feb 17, 2023 - 12:55 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates ~1,900% Better Permeability Through Skin

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its 28th granted patent worldwide and the first granted patent from its sixth patent family, titled Transdermal And/or Dermal Delivery of Lipophilic Active Agents. “The Canadian patent #3,093,414 is for improved compositions and methods for transdermal and dermal delivery of cannabinoids, including cannabidiol (‘CBD’) and tetrahydrocannabinol (‘THC’), all established on the…

Friday Feb 10, 2023 - 1:22 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates Higher Absorption at Lower Dose Levels

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced it had demonstrated superior CBD blood absorption levels from its patented DehydraTECH(TM)-processed CBD compared to those of published comparators. “In their analysis, Lexaria’s researchers compared the average blood plasma levels of DehydraTECH-CBD at various dose levels (after the steady state or the amount of time needed before a consistent dose of drug achieves a stable plasma level had…

Thursday Feb 02, 2023 - 1:28 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Elevate Drug Delivery Across Blood-Brain Barrier by ~1,900%

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed its patented DehydraTECH(TM) technology, which is designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. “DehydraTECH increases effectiveness and improves how these ingredients enter the bloodstream. Benefits of DehydraTECH include: improved speed of onset, with effects felt in minutes; increased bioavailability, with more of the drug delivered into the…

Tuesday Jan 24, 2023 - 11:07 am

InvestorNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Working Toward Global Leadership in CBD Space

Flora (NASDAQ: FLGC) has transitioned from the development stage to a full-scale international distributor with operations in over 12 countries worldwide, achieved under Luis Merchan’s tenure as CEO. “Merchan has also spearheaded several mergers and acquisitions, most notably JustCBD and Vessel Brand, which have since set the company up for rapid growth. Flora also secured $34.5 million in financing and signed deals with key retail…

Thursday Jan 12, 2023 - 2:30 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) in 2022 achieved crucial milestones centered around its patented DehydraTECH(TM) drug delivery technology. “For Lexaria, the end goal does not only lie in uncovering DehydraTECH’s ability to improve the bioavailability of various APIs. Instead, the company is keen on establishing whether DehydraTECH can be applied broadly within the pharmaceutical industry. And calendar 2022 has brought Lexaria closer to realizing this…

Monday Jan 09, 2023 - 1:11 pm

InvestorNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombia, US Facilities to Distinguish Itself Within Highly Competitive Space

Flora Growth Corp. (NASDAQ: FLGC), a cannabis cultivator and global distributor, is a rapidly growing house of brands building customer bases and distribution channels across international lines as it aims to distinguish itself within a highly competitive arena. “Much of Flora Growth’s strength lies in its licensed cultivation, extraction and isolation facility located in northern Colombia’s fertile climate, where an experienced labor force is helping…

Friday Dec 16, 2022 - 3:19 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Expected to Yield Notable Results in Diabetes Study

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs. “Lexaria [recently] announced that the study program DIAB-A22-1 [had begun] on schedule, making it the company’s first-ever study to investigate whether its DehydraTECH-processed cannabidiol (‘CBD’) may potentially have therapeutic utility against diabetes,” a recent article reads. “Lexaria is optimistic that its DehydraTECH-CBD…

Thursday Dec 08, 2022 - 1:47 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Latest DehydraTECH-CBD Study May Be 1st to Evidence Sustained Drop in Blood Pressure

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs, has, since inception, been committed to addressing severe unmet patient needs. Hypertension has been one of its main focus areas. “Lexaria continues to move forward, most recently with the success in its latest human clinical study, HYPER-H21-4. The study may be the first…

Tuesday Nov 22, 2022 - 2:52 pm

InvestorNewsBreaks – Advanced Container Technologies Inc.’s (ACTX) Grow Pods Provide Optimal Environment for all Crops

Advanced Container Technologies (OTC: ACTX) is in the business of developing, manufacturing and selling advanced cultivation equipment, proprietary packaging systems, and a variety of other products to help businesses and entrepreneurs enter or expand in the rapidly growing cannabis and hemp markets. “The company is the exclusive U.S. distributor for Grow Pods, which are advanced, self-contained hydroponic containers that are essentially micro-farms. These containers feature…

Friday Nov 18, 2022 - 12:30 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Treatment Poised to Provide Reprieve to Millions of Patients

Lexaria Bioscience Corp. (NASDAQ: LEXX) is developing a potential hypertension treatment with little to no side effects. “The treatment is created by processing cannabidiol (‘CBD’) using the company’s patented DehydraTECH(TM) drug delivery technology, which has been shown to substantially increase the bioavailability of active pharmaceutical ingredients (‘APIs’). In human studies, Lexaria has shown that DehydraTECH-CBD not only increases the amount of CBD in the blood…

Friday Nov 04, 2022 - 2:01 pm

InvestorNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Increasing Access to Safe, Legal CBD and THC to Global Consumers

Flora Growth Corp. (NASDAQ: FLGC) is a cannabis cultivator, brand manufacturer and global distributor. “The Canadian company with a productive base of operations in Colombia’s fertile greenbelt is licensed to cultivate cannabis on a 100-hectare (about 247-acre) farming facility and then deliver its product to its GMP-certified processing facility in the nation’s capital, where beauty, phytotherapeutic and nutraceutical products are prepared for market…. Flora’s brand…

Wednesday Nov 02, 2022 - 2:07 pm

InvestorNewsBreaks – Advanced Container Technologies Inc. (ACTX) Enabling States to be Agriculture Independent, Grow Food Year-Round

Advanced Container Technologies (OTC: ACTX) is dedicated to developing, manufacturing and selling advanced cultivation equipment, proprietary packaging systems, and a variety of other products. “One of the company’s main business units is focused on selling Grow Pods, which are advanced, self-contained hydroponic containers. These innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with a controlled and specially filtered environment, allow…

Friday Oct 21, 2022 - 3:17 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Holds Potential to Represent Multiple Commercial Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX), a drug delivery platform innovator, last year announced a review of its successful 2021 antiviral drug program. “Lexaria specifically probed the bioavailability of five DehydraTECH(TM)-processed antiviral drugs for SARS-CoV-2, HIV/AIDS and other infectious diseases from three drug classes, evidencing significant gains with up to a three-fold increase in oral drug delivery into the bloodstream. The demonstrated improvements in absorption, Lexaria…

Wednesday Oct 19, 2022 - 2:14 pm

InvestorNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Anticipates Leadership Position in Alternative Cannabinoid Market Segment

Flora Growth Corp. (NASDAQ: FLGC), a global cannabis cultivator, product manufacturer and distributor, is measuring its success in rapidly rising revenues brought on by strategic acquisitions and the expanding international movement of its brands. “The company recently reported a 604% increase YoY in its H1 revenues to about $15 million, which was also a 117% increase over the previous half-year financial report, and is anticipating…

Thursday Oct 13, 2022 - 2:50 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Pipeline Addressing Severe Unmet Patient Needs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a biotechnology company focusing its attention and resources on pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients, developed the patented DehydraTECH(TM) drug delivery technology. “The company has evidenced, through in-vivo, in-vitro and pre-clinical testing, that DehydraTECH delivers more APIs at a faster rate than controls, enabling more effective drug absorption. The testing…

Wednesday Oct 12, 2022 - 2:59 pm

InvestorNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Partnering to Expedite Exports, Increase Global Market Penetration of Colombian Cannabis Goods

Flora Growth Corp. (NASDAQ: FLGC), a global cannabis brand builder, is increasing the strengths of its supply chain, centered in its 100-hectare (about 247-acre) cultivation facility located in the heart of Colombia’s green climate, by finalizing a three-year distribution agreement with the Misak indigenous tribe’s pharmaceutical arm. “Pharma Indigena Misak Manasr Sas, referred to simply as Manasr, is the tribe’s pharmaceutical enterprise, which in 2020…

Thursday Oct 06, 2022 - 2:32 pm

InvestorNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Elevating Performance with Expanded Team

Flora Growth Corp. (NASDAQ: FLGC), throughout 2022, has been implementing its hiring strategy that has seen the appointment of several key individuals whose proven talents and productivity are critical to the company’s goal of delivering the most compelling customer experiences. “Flora Growth ushered in the new year with the appointment of Tim Leslie as chairman of its newly formed advisory board. It would later bring…

Thursday Oct 06, 2022 - 2:16 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Redefining Drug Delivery Platforms

Lexaria Bioscience Corp. (NASDAQ: LEXX) has remained committed to improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. “Moreover, as a global innovator in drug delivery platforms, the company has not shied away from advancing its research to cut across various health conditions, including but not limited to hypertension, epilepsy, diabetes, and dementia, among others. These efforts have yielded 27 granted patents around the…

Friday Sep 30, 2022 - 1:31 pm

InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Expand Indications, Efficacy of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently received its 27th worldwide patent, granted in Mexico under registration #390001. “The patent applies to a range of active ingredients, including but not limited to non-psychoactive cannabinoids and NSAIDs in a wide variety of ready-to-drink consumer retail beverage products. The latest patent provides value to the company through its continued pursuit of…

Thursday Sep 15, 2022 - 1:35 pm

InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Hypertension Treatment Program Stands Distinct

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently provided information to its stakeholders to help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. The information includes a discussion of underlying logic-based evaluations that offer a realistic framework of expectations that investors can use in their analysis. “One of the logic-based evaluations considers the stage at which a…

Wednesday Sep 07, 2022 - 10:32 am

InvestorNewsBreaks – BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Releases Shareholder Update with Corporate, Operational Highlights

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), an innovative health and wellness beverages and products company, has released a shareholder letter from BevCanna CEO Marcello Leone and CFO John Campbell. Highlights of the report included an update on the status of the company’s temporary cease trading position, with the letter observing that “increased complexity of valuing the company’s holdings delayed the completion of its annual…

InvestorNewsBreaks

NewsBreak Category: Hemp

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions